MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Tandem Diabetes Care Gross Profit 2011-2026 | TNDM
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Tandem Diabetes Care
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 167 M | 157 M | 368 M | 413 M | 376 M | 261 M | 194 M | 89.8 M | 44.1 M | 23.6 M | 26.6 M | 15.2 M | 6.17 M | -1.35 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 413 M | -1.35 M | 153 M |
Quarterly Gross Profit Tandem Diabetes Care
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 137 M | 134 M | 126 M | 118 M | - | 125 M | 113 M | 94.7 M | - | 89.8 M | 102 M | 82.9 M | - | 104 M | 102 M | 91.1 M | 114 M | 96.7 M | 92.5 M | 73.3 M | 90.6 M | 65.3 M | 54.4 M | 50.3 M | 60.3 M | 50.7 M | 49.9 M | 33.4 M | 41.5 M | 21.8 M | 15.1 M | 11.4 M | 17.5 M | 11.9 M | 8 M | 6.75 M | 10.1 M | -1.58 M | 8.18 M | 6.93 M | 13.5 M | 5.51 M | 4.8 M | 2.81 M | 6.54 M | 4.4 M | 3.45 M | 867 K | 1.19 M | 2.53 M | 406 K | 2.04 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 137 M | -1.58 M | 50.1 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
26.6 M | - | - | $ 162 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | USA |
 |
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
275 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | USA |
 |
ClearPoint Neuro
CLPT
|
22.7 M | $ 13.55 | -0.29 % | $ 384 M | USA |
 |
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
532 M | $ 8.2 | -0.73 % | $ 1.23 B | USA |
 |
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
18 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
19.2 M | $ 1.14 | 1.79 % | $ 19.3 M | USA |
 |
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | USA |
 |
Helius Medical Technologies
HSDT
|
5.52 M | $ 1.46 | -1.31 % | $ 32.2 M | USA |
 |
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | USA |
 |
Cytosorbents Corporation
CTSO
|
26.5 M | $ 0.42 | -1.18 % | $ 26.1 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
173 M | $ 18.57 | 0.41 % | $ 436 M | USA |
 |
Delcath Systems
DCTH
|
73.4 M | $ 11.53 | -1.37 % | $ 413 M | USA |
 |
LivaNova PLC
LIVN
|
940 M | $ 78.1 | 1.21 % | $ 4.26 B |  Britain |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | USA |
 |
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.51 | -1.63 % | $ 61.4 M | USA |
 |
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M |  Canada |
 |
LENSAR
LNSR
|
14.1 M | $ 5.74 | 0.88 % | $ 68.6 M | USA |
 |
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
50 M | $ 37.28 | 2.73 % | $ 315 M | USA |
 |
MiMedx Group
MDXG
|
346 M | $ 3.72 | 0.13 % | $ 550 M | USA |
 |
Butterfly Network
BFLY
|
45.7 M | $ 5.46 | 6.54 % | $ 1.35 B | USA |
 |
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | USA |
 |
Myomo
MYO
|
26.9 M | $ 1.51 | 14.02 % | $ 63.2 M | USA |
 |
Orthofix Medical
OFIX
|
566 M | $ 9.9 | 0.3 % | $ 392 M |  Curacao |
 |
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
1.02 B | $ 81.47 | -1.27 % | $ 11 B | USA |
 |
Insulet Corporation
PODD
|
1.94 B | $ 155.47 | -2.59 % | $ 10.9 B | USA |
 |
Profound Medical Corp.
PROF
|
11.4 M | $ 6.9 | 1.17 % | $ 209 M | Canada |
 |
CONMED Corporation
CNMD
|
750 M | $ 36.3 | -1.63 % | $ 1.13 B | USA |
 |
Inspire Medical Systems
INSP
|
779 M | $ 42.87 | 1.56 % | $ 1.26 B | USA |
 |
Integer Holdings Corporation
ITGR
|
500 M | $ 92.79 | -1.39 % | $ 3.22 B | USA |
 |
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
4.73 B | $ 86.46 | -1.24 % | $ 50.6 B | USA |
 |
Sintx Technologies
SINT
|
461 K | $ 2.11 | -1.86 % | $ 5.85 M | USA |